Clifford Swan Investment Counsel’s Eli Lilly LLY Stock Holding History

Clifford Swan Investment Counsel’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.14M	Sell	3,416 -60	-2%	-$60.8K	0.11%	131
2025 Q4	$3.74M	Sell	3,476 -84	-2%	-$80.3K	0.12%	123
2025 Q3	$2.72M	Sell	3,560 -70	-2%	-$52.1K	0.09%	135
2025 Q2	$2.83M	Sell	3,630 -1,476	-29%	-$1.15M	0.1%	135
2025 Q1	$4.22M	Buy	5,106 +12	+0.2%	+$9.98K	0.16%	118
2024 Q4	$3.93M	Sell	5,094 -166	-3%	-$137K	0.14%	120
2024 Q3	$4.66M	Buy	5,260 +259	+5%	+$233K	0.17%	111
2024 Q2	$4.53M	Sell	5,001 -32	-0.6%	-$25.6K	0.17%	111
2024 Q1	$3.92M	Sell	5,033 -51	-1%	-$36.3K	0.15%	118
2023 Q4	$2.96M	Sell	5,084 -248	-5%	-$145K	0.12%	125
2023 Q3	$2.86M	Buy	5,332 +18	+0.3%	+$9.28K	0.12%	122
2023 Q2	$2.49M	Buy	5,314 +585	+12%	+$245K	0.1%	130
2023 Q1	$1.62M	Sell	4,729 -403	-8%	-$136K	0.07%	145
2022 Q4	$1.88M	Sell	5,132 -18	-0.3%	-$6.38K	0.08%	138
2022 Q3	$1.67M	Hold	5,150	–	–	0.08%	141
2022 Q2	$1.67M	Buy	5,150 +66	+1%	+$19.8K	0.07%	143
2022 Q1	$1.46M	Sell	5,084 -150	-3%	-$38.6K	0.05%	158
2021 Q4	$1.45M	Sell	5,234 -70	-1%	-$17.7K	0.05%	161
2021 Q3	$1.32M	Buy	5,304 +200	+4%	+$49.4K	0.05%	170
2021 Q2	$1.34M	Sell	5,104 -25	-0.5%	-$5.02K	0.05%	160
2021 Q1	$958K	Sell	5,129 -25	-0.5%	-$4.89K	0.04%	182
2020 Q4	$870K	Sell	5,154 -76	-1%	-$11.3K	0.04%	185
2020 Q3	$774K	Buy	5,230 +1	+0%	+$155	0.04%	188
2020 Q2	$858K	Sell	5,229 -60	-1%	-$9.21K	0.04%	172
2020 Q1	$734K	Buy	5,289 +70	+1%	+$9.62K	0.04%	174
2019 Q4	$686K	Hold	5,219	–	–	0.03%	194
2019 Q3	$584K	Hold	5,219	–	–	0.03%	194
2019 Q2	$578K	Sell	5,219 -301	-5%	-$35.4K	0.03%	195
2019 Q1	$716K	Sell	5,520 -1,300	-19%	-$158K	0.04%	177
2018 Q4	$789K	Sell	6,820 -25	-0.4%	-$2.79K	0.05%	165
2018 Q3	$735K	Sell	6,845 -520	-7%	-$52K	0.04%	174
2018 Q2	$628K	Sell	7,365 -655	-8%	-$53.8K	0.04%	187
2018 Q1	$621K	Sell	8,020 -360	-4%	-$29K	0.04%	189
2017 Q4	$708K	Buy	8,380 +1,000	+14%	+$85.1K	0.04%	185
2017 Q3	$631K	Buy	7,380 +190	+3%	+$15.6K	0.04%	193
2017 Q2	$592K	Sell	7,190 -125	-2%	-$10.2K	0.04%	205
2017 Q1	$615K	Buy	7,315 +259	+4%	+$20.7K	0.04%	191
2016 Q4	$519K	Sell	7,056 -14	-0.2%	-$1.04K	0.03%	194
2016 Q3	$567K	Buy	7,070 +1,180	+20%	+$94.4K	0.04%	185
2016 Q2	$464K	Sell	5,890 -10,650	-64%	-$802K	0.03%	190
2016 Q1	$1.19M	Buy	16,540 +492	+3%	+$37.2K	0.08%	139
2015 Q4	$1.35M	Buy	16,048 +3,369	+27%	+$280K	0.09%	135
2015 Q3	$1.06M	Sell	12,679 -968	-7%	-$81.7K	0.08%	142
2015 Q2	$1.14M	Sell	13,647 -428	-3%	-$32.6K	0.08%	138
2015 Q1	$1.02M	Sell	14,075 -498	-3%	-$35.5K	0.07%	138
2014 Q4	$1M	Sell	14,573 -224	-2%	-$15.1K	0.07%	140
2014 Q3	$960K	Sell	14,797 -620	-4%	-$39.3K	0.07%	141
2014 Q2	$958K	Buy	15,417 +1,601	+12%	+$95.5K	0.06%	144
2014 Q1	$813K	Buy	13,816 +7,651	+124%	+$427K	0.06%	143
2013 Q4	$314K	Hold	6,165	–	–	0.02%	194
2013 Q3	$310K	Hold	6,165	–	–	0.02%	190
2013 Q2	$303K	Buy	+6,165	New	+$335K	0.03%	188

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Clifford Swan Investment Counsel's LLY Position: Q1 2026 in Review

Clifford Swan Investment Counsel reduced its Eli Lilly (LLY) stake by 1.7% in Q1 2026, selling an estimated $60.8K and leaving 3,416 shares worth $3.14M. The position accounts for 0.11% of the portfolio, ranked #131.

Clifford Swan Investment Counsel first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.66M in Q3 2024. 4,362 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

Clifford Swan Investment Counsel held 3,416 shares of Eli Lilly worth $3.14M as of Q1 2026.
Clifford Swan Investment Counsel sold 60 Eli Lilly shares in Q1 2026, an estimated $60.8K.
Eli Lilly made up 0.11% of Clifford Swan Investment Counsel's portfolio in Q1 2026, its #131 holding.
Clifford Swan Investment Counsel first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
Clifford Swan Investment Counsel's Eli Lilly position peaked at $4.66M in Q3 2024.
4,362 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Clifford Swan Investment Counsel's 13F filing for Q1 2026, filed 6 May 2026.